BOT - Anything but charting, page-8306

It’s my belief that the sell-off this week is folks prudently (or otherwise) reducing FDA risk. While the risk is largely mitigated at this point, it still exists, and if over the short time horizon per the hartleys report you believe the full value is 33c, taking some off is likely sensible given the asymmetrical profile at 29c.

However, for those of us here for the structural multi year journey, the FDA announcement is a only a data point, one that no doubt has significant consequence, but that’s not the investment thesis. The long term thesis requires this approval, but extends far beyond it, and far beyond 33c (or the equivalent market cap).

for me, as it relates to BOT, it’s like watching a man walking up a hill holding a yo-yo. I’m watching the man walk up the hill, not the yo-yo.